CGIM
SAGE

Cannon Global Investment Management’s Sage Therapeutics SAGE Stock Holding History

Cannon Global Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,500
Closed -$296K – 92
2025
Q2 		$296K Buy
+32,500
New +$239K 0.61% 51

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cannon Global Investment Management's SAGE Position: Q3 2025 in Review

Cannon Global Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 32,500 shares — an estimated $296K sold.

Cannon Global Investment Management first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $296K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Cannon Global Investment Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 32,500 Sage Therapeutics shares in Q3 2025, an estimated $296K.
  • Cannon Global Investment Management first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Cannon Global Investment Management's Sage Therapeutics position peaked at $296K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Cannon Global Investment Management's 13F filing for Q3 2025, filed 28 Oct 2025.